300676.SZ
华大基因
SZSE · Healthcare · M 科研服务 · CN
CNY 41.90
−0.71%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 3.8B | 3.7B | 3.9B | 4.3B | 7.1B |
| Cost of Revenue | 2.4B | 2.3B | 2.3B | 2.2B | 3.4B |
| Gross Profit | 1.4B | 1.4B | 1.6B | 2.2B | 3.7B |
| Operating Expenses | |||||
| R&D Expense | 428.3M | 456.9M | 606.2M | 528.9M | 535.8M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 319.6M | 329.7M | 409.5M | 398.8M | 381.1M |
| Selling & Marketing Expense | 771.1M | 774.7M | 1.0B | 1.0B | 1.6B |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 1.5B | 1.5B | 2.0B | 1.9B | 2.5B |
| Cost and Expenses | 3.9B | 3.8B | 4.3B | 4.1B | 5.9B |
| Operating Income (EBIT) | (536.9M) | (593.2M) | (874.8M) | 150.6M | 1.1B |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (543.8M) | (602.3M) | (886.1M) | 115.5M | 1.0B |
| Income Tax Expense | 48.6M | 35.5M | 26.0M | 21.9M | 197.5M |
| Bottom Line | |||||
| Net Income | (573.5M) | (616.7M) | (902.7M) | 92.9M | 802.8M |
| Earnings from Cont. Ops | (592.4M) | (637.8M) | (912.1M) | 93.7M | 809.3M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (573.5M) | (616.7M) | (902.7M) | 92.9M | 802.8M |
| Per Share | |||||
| Basic EPS | (CN¥1.38) | (CN¥1.48) | (CN¥2.19) | CN¥0.23 | CN¥1.96 |
| Diluted EPS | (CN¥1.38) | (CN¥1.48) | (CN¥2.19) | CN¥0.23 | CN¥1.97 |
| Revenue Per Share | CN¥9.24 | CN¥8.90 | CN¥9.38 | CN¥10.61 | CN¥17.19 |
| Shares | |||||
| Basic Shares Outstanding | 415.7M | 416.3M | 412.4M | 410.0M | 410.4M |
| Diluted Shares Outstanding | 415.7M | 416.3M | 412.4M | 410.0M | 410.4M |
| Profitability Metrics | |||||
| EBITDA | — | (59.2M) | (381.9M) | 556.6M | 1.5B |
| D&A | — | 533.9M | 492.9M | 406.0M | 391.7M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026